Myomo, Inc. (MYO) Earnings Call Transcript
March 9, 2026
Earnings Call Speaker Segments
Thanks, operator. Good afternoon, everyone; Tirth Patel here, calling in with Alliance Advisors IR. I'd like to welcome all of you to the conference call covering Myomo's financial results for the fourth 1/4 and the entire 2025 fiscal year. Joining me on today's call are Myomo's Chief Executive Officer, Paul Gudonis, and Chief Financial Officer, David Henry. Before we get started, I want to remind listeners that anything management says during this call that isn't a historical fact constitutes a Forward-Looking statement. You'll typically see such forward-looking statements flagged by words like anticipate, believe, estimate, expect, intend, guidance, outlook, confidence, target, project, and other similar expressions. Statements of that kind looking ahead can't be relied on as promises about how things will turn out, and they carry exposure to dangers, unknowns, and additional elements that could impact Myomo's operations, its financial position, and the results it reports; those dangers, unknowns, and additional elements get covered in the documents Myomo files with the Securities and Exchange Commission. What actually happens, and the results we ultimately see, could end up substantially different from anything stated or suggested by these forward-looking statements. Unless the law demands it, Myomo accepts no duty to amend or refresh any forward-looking statements to account for occurrences or situations arising after today's call, March 9, 2026. At this point I'm happy to hand things over to Myomo CEO, Paul Gudonis. Paul, the floor is yours.
Thanks, Tirth. Good afternoon, everyone, and thanks for being with us today. On our previous quarterly call, I laid out four key goals for the business. First, keep growing revenue via our direct-to-patient marketing, and also expand order volume from recurring sources — specifically the Orthotics and Prosthetics channel plus the MyoConnect referral program. Second, improve patient access to the market by securing more payer contracts and working with Medicare Advantage and commercial plans on coverage. Third, control our cost structure and improve manufacturing operations so we can show operating leverage as we scale. Fourth, keep innovating on the product side to hold onto our leadership position in the market. I'm happy to say we've made headway on each of those four goals. Q4 of 2025 delivered the highest revenue of any quarter this year, at $11.4 million. That took our full year revenue to $40.9 million, which is 26% growth versus 2024. We also set a record for order volume in the company's history, with 241 MyoPros ordered in the quarter, a 5% sequential increase over Q3. The drivers behind that growth were deeper penetration of the O&P channel, early traction from our MyoConnect clinical referral program, and stronger international revenues. During the past year, we introduced the MyoPro Center of Excellence program, which educates domestic O&P practices about the new MyoPro 2X product and the improved reimbursement environment. O&P providers — ranging from national and regional chains to local independent practices — ordered roughly 100 MyoPros last year. On top of that, quarterly revenue from the U.S. O&P channel passed $1 million for the first time, and our O&P channel revenue rose 81% for the quarter and doubled for the year. To build on the clinical relationships we've established with therapists at rehab hospitals nationwide, we created the MyoConnect program, which gets therapists and physicians involved in referring medically qualified patients to Myomo and our O&P partners. In only the first 6 months of this program, more than 100 qualified candidates have entered our patient pipeline, and referrals accounted for nearly 10% of total pipeline adds in Q4. We'll keep leaning into MyoConnect in 2026 as we concentrate on growing revenues from recurring patient sources. MyoConnect resonates with clinicians because they want better outcomes for their patients, and these rehab hospitals will keep providing therapy and training support under the MyoPro protocol. This strategic pivot toward recurring patient sources is already showing up in our results. Back in Q4 of 2024, 26% of our revenue came from recurring sources. By Q4 of 2025, that number had risen to 42%, which is 52% Year-Over-Year growth. Underpinning the revenue initiatives above is a revised marketing plan that's building awareness of our products among healthcare professionals and further optimizing our digital marketing to patients. We believe these efforts, together with better insurance coverage, will bring down our acquisition costs per customer. For the first time ever, overseas sales came in above $2 million in a quarter, with a 46% jump for the 1/4 and 48% for the year. That gain came from a bigger patient pipeline, additional O&P clinics and medical professionals referring patients to MyoPro, supportive reimbursement rules from statutory health insurers, and some favorable foreign exchange movement. We're bringing on additional business development and clinical personnel in Germany, and we anticipate that market will keep expanding in 2026. Turning to China, late in the year we learned that Ryzur Medical, the majority shareholder in the joint venture, encountered financial trouble in its main rehab hospital business and filed for bankruptcy. Because of that, the JV company's operations are currently suspended. As you might remember, a few years back we collected $2.7 million in upfront license payments, and at present we're collaborating with China Lead Ventures, a significant JV investor, to explore whether the venture can be recapitalized and restructured so it can pursue that enormous market opportunity in that country. Our U.S. market access approach keeps building momentum, and over the past several months we've signed in-network contracts with additional Medicare Advantage and commercial payers. Most notably, we recently struck a multi-state agreement with Elevance Health, letting us start executing State-By-State in-network contracts throughout their network, which reaches 45 million lives. This marks our first arrangement of this breadth with a payer, and it provides for case-by-case authorization. That matters because we're seeing a rising number of authorizations from plans where a contract is in place. Because pricing is already agreed, there's no need to go through a lengthy single case agreement process, which accelerates the patient's access to MyoPro as well as our revenue cycle. Our 1/3 major initiative involves managing our cost structure. We've acted to boost organizational efficiency, cut spending on outside services, and keep driving down material costs for manufacturing the MyoPro units. We're getting more efficient while still investing in key R&D projects to extend our market leadership. In Q2 of this year, we intend to launch the Myomo mobile app for patients and clinicians, which is currently offered as a free download in the Apple and Google App Stores. The app delivers enhanced capabilities and data collection for users, while letting us lower the cost of goods sold by removing the need to ship a laptop, loaded with our proprietary software, to every MyoPro user. At the same time, we anticipate introducing other enhancements this year as we develop the next generation MyoPro 3. Another R&D investment we're making is in a randomized controlled trial being run by the Craig H. Neilsen Rehabilitation Hospital, and it should contribute to the expanding body of research publications, such as the 2 that came out last year. To wrap up, our shift toward recurring sources of patients is moving ahead well, we've seen a greater volume of insurance authorizations along with orders through the O&P channel, and our cost structure is now leaner, since our goal is to reduce cash burn by 50% during 2026. Having given that look at our results and the steps we've taken, I'll now hand things over to David Henry, our CFO, who will walk through more of the financial figures and specifics.
Thanks, Paul, and good afternoon to all of you. As Paul noted, our revenue for the full year grew 26%, with gains coming from every one of our sales channels, and the U.S. O&P channel along with international led the way, as both posted record 1/4s. For the fourth 1/4 of 2025, revenue came in at $11.4 million, marking our strongest revenue 1/4 of the year, a rise of 13% over the 1/3 1/4 of 2025, though it was modestly below the same period a year earlier. That Year-Over-Year decline stemmed from fewer revenue units along with a somewhat reduced average selling price, or ASP. On top of that, during the fourth 1/4 of 2024, we had stronger Medicare Advantage revenue and met pent-up demand from Medicare patients after we started covering the MyoPro earlier in that year. We delivered 208 MyoPro revenue units in the 1/4, a drop of 5% Year-Over-Year, yet a sequential gain of 12%. Authorizations received during the 1/4 accounted for 62% of fourth 1/4 revenue units; moreover, our ASP fell by under 1% from the prior year, landing at roughly $54,600, mainly because of channel mix. Medicare Part B patients made up 49% of revenue in the fourth 1/4. Medicare Advantage patients accounted for 20% of fourth 1/4 revenue and, measured in dollars, declined 11% from the prior year 1/4. You have surely observed this at other companies, but it has been a difficult year working with Medicare Advantage payers, who have held things back by issuing a large volume of pre-authorization denials, which forces an appeals process so we can serve these patients. We have fought these denials and will keep fighting them to get our product to patients who need it. With each new payer contract we sign, we see more authorizations coming through those agreements. That has not yet been sufficient to make up for the volume from payers that used to authorize more routinely; we keep working to land additional payer contracts and are heartened by our first multi-state payer arrangement with Elevance. Direct billing accounted for 69% of revenue in the fourth 1/4, versus 81% in the prior year 1/4. Direct billing revenue fell 20% Year-Over-Year, the result of fewer Medicare and Medicare Advantage authorizations as well as social media lead generation difficulties we encountered in the first 1/2 of 2025. Solid results in our other sales channels partly made up for the lower direct billing revenue. International revenue hit a record $2.2 million, rising 46% Year-Over-Year and making up 19% of total revenue, mostly from Germany. The U.S. O&P channel likewise hit a milestone, getting to a record $1 million in quarterly revenue, an 81% Year-Over-Year increase that accounted for 9% of total revenue. Recurring patient sources — among them referrals through our MyoConnect program, international, U.S. O&P, and the VA — made up 42% of fourth 1/4 revenue. The pipeline totaled 1,528 patients as of December 31st, 2025, which is 10% higher Year-Over-Year. In the fourth 1/4, 676 patients were added to the pipeline, a 3% increase over the prior year 1/4. We finished the 1/4 with a backlog of 199 patients. During the fourth quarter, we booked a record 241 orders. Paired with operations that ran without a hitch, that produced a record: 62% of fourth-quarter revenue units came from units filled within the same quarter, versus 35% of revenue units one year earlier. For the fourth quarter of 2025, gross margin stood at 68.6%, which is lower than 71.4% a year ago yet higher than 63.8% in the third quarter. The decline versus last year came from less overhead being capitalized into inventory than in the prior-year period, plus greater warranty expenses. Operating expenses in the fourth quarter of 2025 reached $10.6 million, a 19% rise over the prior-year quarter. That increase stemmed mainly from greater sales, clinical and marketing costs, especially advertising expense, which rose roughly $1.2 million year over year. Sequentially, advertising spending in the fourth quarter fell 4%. Our operating loss for the fourth quarter of 2025 was $2.8 million, versus an operating loss of approximately $200,000 in the prior-year quarter. Non-operating expenses in the fourth quarter include a one-time write-off of debt issuance costs, cash interest expense under the Avenue term loan, non-cash interest expense from amortization of debt discounts, and a loss from the change in fair value of derivative liabilities that were bifurcated from the debt on the issuance date and recorded as separate liabilities, which have to be marked to market at fair value every quarter. Net loss for the fourth quarter of 2025 came to $3.8 million, or $0.09 per share. That compares with a net loss of $300,000, or $0.01 per share, for the fourth quarter of 2025. Adjusted EBITDA for the fourth quarter of 2025 was negative $1.9 million, versus positive $200,000 for the fourth quarter of 2024. Before turning to the balance sheet, let me quickly summarize a few selected full-year results. As I noted, revenue reached $40.9 million, an increase of 26%. Gross margin for the year was 65.7%, versus 71.2% for 2024. That decline resulted from higher overhead costs, largely because of our facility move earlier this year. Investments in R&D — which led to the launch of the MyoPro 2X, our Mark 2 unit, and progress on the MyoPro 3 in 2025 — along with greater sales and marketing expense, pushed operating expenses up to $41.3 million in 2025, compared with $29.4 million in 2024. Now to our balance sheet and cash flow. As of December 31st, 2025, cash equivalents and short-term investments totaled $18.4 million. Cash burn, which we define as free cash flow, was $1.5 million in the fourth quarter, excluding net proceeds from the Avenue term loan, repayment of the debt to Silicon Valley Bank, and issuance fees and expenses. Operating cash flow was negative $1.1 million in the quarter, compared to positive $3.4 million in the fourth quarter a year ago. Let me wrap up my remarks with financial guidance. Like Paul said, we're heading into 2026 treating it as a year in which we steer the company further toward stroke patients within the incidence population and toward recurring patient sources via our MyoConnect referral program, while also deepening engagement with the U.S. O&P channel and continuing to expand internationally. Getting a majority of revenue from recurring sources is our near-term aim, and we think that will make scaling the business simpler. To pay for this shift, we'll keep advertising direct to patients, though we'll restrain how much advertising spending grows while we build out MyoConnect and bring on direct sales resources for the O&P and international channels. Keep in mind that first 1/4 revenue is usually seasonally weaker and expenses run higher, since payroll taxes and employee benefits reset. Consistent with that historical seasonality, we anticipate first 1/4 revenue falling in the range of $9 million-$9.5 million; because revenue is expected to be sequentially lower and operating expenses are expected to be slightly higher sequentially, we anticipate the first 1/4 operating loss will exceed the fourth 1/4 2025 figure. For 2026, our revenue expectation is a range of $43 million-$46 million. We anticipate gross margin gaining from higher volume and a lower cost of goods sold per unit, plus a 2% Medicare price increase effective January 1, 2026. Beyond that, we anticipate generating operating leverage and restraining the growth of other operating expenses. We intend to hold OpEx growth to 1/2 of revenue growth in 2026; given gross margin is expected to rise in 2026 along with operating cost management, we anticipate a smaller operating loss in 2026, and that cash burn or free cash flow will be cut by roughly 1/2 in 2026 versus 2025, driven by the higher revenue and gross margin, partially offset by investment in R&D and sales and marketing, as well as interest expense on our debt. We're dedicated to growing the top line while investing prudently in the business; with that overview, I'll hand the call back to Paul.
Thanks, David. So to put it in a nutshell, during 2025 our revenue rose by 26%. We brought the MyoPro 2X to market. We put money into creating the next-gen MyoPro 3; orders from the new O&P channel brought in several million dollars. The recurring revenue piece of our business was Re-Grown by more than 50%; we also widened our addressable market by reaching patients immediately following their stroke while they remain in the rehab centers, along with the sizable prevalence population dealing with chronic arm paralysis. As an illustration, we recently gave a MyoPro to a 36-Year-Old male whose stroke happened last year and whom his therapist referred to us. Through our contract with his Blue Cross Blue Shield plan, he got approved for the device quickly and had it within a year of the incidence of his stroke. Looking toward this year, our plan is to keep up this go-to-market transition, bring down our customer acquisition costs, and show that operating leverage with a lower cost structure. Even so, the untapped market for our product stays vast, with hundreds of thousands of potential patient candidates representing a large long-term opportunity. Because of our sales and marketing transition and the uncertainty around how the Medicare Advantage payers will behave, we think it's prudent to be conservative and guide to approximately 10% revenue growth with improvement in adjusted EBITDA. We look forward to updating you on our progress as the year unfolds. We're now ready to take your questions. Operator? While we're waiting for the first question. Well, yeah. Chuck, I was gonna say, while we're waiting for the first question, I do wanna mention that we're planning to host another investor analyst day for an update on the business, and we'll provide details on this event at a later date; we hope to speak with many of you there. Okay, operator, let's go with the first question.
Hello, and thank you for allowing me to ask. To begin, you mentioned improvement with MyoConnect, but the expense for each pipeline ad apparently rose during the 1/4. Could you explain what likely caused that rise in the 1/4? After that, could you discuss the approach for the direct portion of the company to bring that customer acquisition expense down? Thank you.
Thank you, Chase. The MyoConnect initiative is building momentum. Referrals are coming in, and those carry a 0 advertising cost. During the fourth 1/4, which we have previously discussed, advertising tends to cost more since you are up against holiday promotions. In certain situations, election cycles may also be a factor. Once you divide our pipeline ads by the advertising expenses, the result was greater than what we would prefer. Our response has been to hire a new marketing leader. Her start date was at the close of last year. In January, we engaged a different digital marketing firm. They have begun overhauling our digital marketing strategy along with social media. We launched fresh TV creative for that campaign, and the cost per call has declined. We anticipate that each of these steps ought to reduce the cost per pipeline ad eventually, particularly as referrals grow, since those come with a 0 advertising cost.
As we've sort of moved into Q1, have you observed any of that progress yet?
Well, at this point we aren't actually talking about Q1. That said, I'd note it's somewhat early. The ad agency, I'd say, only truly got going during the past 6 to 8 weeks — you know, genuinely beginning to, you know, carry out their efforts. Right now it's a bit too soon to discuss what's coming of it. My sense is we'll provide a stronger update in May, when we report the first 1/4 results.
Understood. Perhaps a few additional specifics regarding the O&P channel would help. Could you share any type of metrics related to order volume — for instance, how many clinics placed orders during the 1/4, or some measure of active accounts? Would you provide the unit count for the O&P channel in Q4? Did ASP remain fairly stable from Q3 to Q4? Thanks.
Around two dozen O&P providers have completed training and certification and are now purchasing MyoPros, and revenue for the 1/4 exceeded $1 million. At a typical price point, that's roughly 30-something units. Dave?
It was about 36 O&P units in the fourth 1/4.
Understood. For my final question, regarding the 2026 guidance, could you lay out the assumptions behind what the U.S. O&P business will contribute to that 2026 outlook?
Sure, we anticipate expansion in both the O&P channel and internationally. Those areas will fuel this year's growth. Looking at direct billing, I'd say it will stay fairly level. The reason is that we're simply not far enough along with these marketing adjustments to feel confident enough to claim that direct billing will increase. We're attempting to cap our advertising expenditure since we've observed the outcomes during the latter half of 2025, and the cost per pipeline ad is unacceptably high. We must see that issue resolved before we choose to allocate additional funds toward advertising past what we're currently spending. The MyoConnect program is truly accelerating. There are certain uncertainties as we await how these marketing adjustments will ultimately affect things, so we can gain clearer insight into what that channel may look like for 2026. We're putting in serious effort to expand those recurring patient sources because, as Paul noted, the cost per pipeline ad in that area is minimal, and our focus is on boosting operating leverage and cutting cash burn while simultaneously increasing revenue in 2026.
Got it. Thanks.
Thanks. Good afternoon. If we begin at the top of the funnel with pipeline ads, 676 comes in somewhat below where it sat during the prior couple of quarters. Would you call that an anomaly? Are the ads you're receiving of better quality? Or, put differently, ought we to expect a rebound toward a few of those elevated marks from the middle of the year? Thanks.
Yeah. What I'd say is that one crucial factor will be whether MyoConnect succeeds at producing pipeline ads. Look, we aren't raising our advertising outlay. Our plan is to hold that spend fairly level Year-Over-Year. Those are the places the sources will come from. You're correct that we had 676. That number was somewhat lower. Still, I'd note that we closed things down across roughly the final 9 days of 2025. That had a modest impact on generating pipeline ads. Within the fourth 1/4, we had around 2 fewer weeks than we did in the 1/3. As I mentioned, I believe we're genuinely hoping to watch the MyoConnect program pick up momentum and attempt to deliver additional pipeline ads at a far lower cost per pipeline ad in 2026.
Alright, we'll keep monitoring that. Additionally, the dropout rate, based on my math, came to roughly 40%. I suppose that figure might shift slightly depending on the method used. It's a touch elevated, though not significantly so compared to prior 1/4s — any thoughts on that number?
You're referring to the backlog drop rate, right?
Okay.
Right. Based on what I figured, it came in slightly above 20%.
Alright. The pattern ought to hold, it just depends... I'm simply deriving it from the reimbursement pipeline. When you take every ad and then remove the units that were placed, that gives you a figure.
Right. What you'd be describing there, I'd call it a pipeline drop rate.
Yes.
David Henry, the respondent: All right. Yes. Backlog was the subject I had in mind. My apologies.
Oh.
I haven't worked out what the pipeline drop rate is. I'll trust what you're saying — it was roughly that. What I mean is, there's.
That's slightly above...
Yes, so regarding the total pipeline, the pipeline went down, and much of that likely stemmed from drops. A significant number of Medicare Advantage patients have been building up in the pipeline that we have, and, you know, they're making authorization difficult for us; consequently, many of them, you know, we're observing quite a few drop-offs because of that.
All right.
Conversely, Scott, what we're noticing is that, particularly from the referring therapist—since we've urged them to, you know, verify insurance and such—we're getting more patients who qualify for Medicare arriving through their referral channel, which means, you know, there's a greater chance they'll be approved for their MyoPro.
Alright. Thanks for the detail. Last question: gross margins came in really strong in the 1/4, and in the press release at least, you said they might climb even higher. Starting from that roughly 68%-69% mark, could that become a fresh baseline? How far up can it realistically go? Since clearly that's a solid figure for the 1/4.
Yes; volume will cause it to move around, and I'd anticipate first 1/4 gross margin to be beneath fourth 1/4 simply due to, you know, fewer units soaking up overhead. Over the course of the year, you know, the, you know, the guidance suggests rising revenues as we move through the 1/4s of 2026. That's going to support gross margin along with, you know, we're, you know, we're pursuing roughly, as we actually said at last Analyst Day, about 200 basis points of gross margin gain through a range of initiatives. Paul brought up the mobile app, which we expect will launch in the next few weeks; that's going to assist, you know, in removing roughly $400-$500 of cost from the MyoPro since we no longer supply a laptop. Additional cost reduction efforts are underway too. We, you know, so I believe that, we're aiming to bring that gross margin back into the, into the 70% range by the time 2026 comes to an end.
All right, excellent. Thanks for fielding the questions.
Mm-hmm.
Thanks for taking my question. The first one had to do with the O&P clinics. If I remember right, during last year's investor day you said the plan was to have about 200 clinics trained, certified, and capable of delivering the MyoPro in 2028. Is that still a goal that's on track? How quickly is this O&P ne2rk growing?
That remains one of our goals. We have quite a few clinics that are at an earlier stage, where they're only now being trained. They're developing their patient pipelines. They're securing the reimbursement, and after that they'll convert into orders. We also have very strong national account programs, since there's been consolidation in the industry, with a number of players owning 40 to 50, 80 or so clinics, and we've been doing national account planning with these entities, where they begin with a couple of their regions, pilot it, get some good results, and then we'll see a broader rollout. I think, look, this is the most powerful new product opportunity to address a big unmet need. I'm very bullish about the O&P channel adopting the MyoPro into their clinical treatment plans.
All right, that's helpful. So let me pivot, if I may, to how long it takes to get paid. In the past, as I recall, you've said on several occasions that it takes about 6 months from the moment a patient first gets in touch to the point where the money actually arrives. With you now bringing on additional payers, has that collection timeline gotten any shorter, or does it still sit at about 6 months?
I'd say the more meaningful gain stems from the fact that Medicare currently accounts for approximately 1/2 of what we bring in. Turnaround from Medicare tends to be fast. Typically, we receive funds within 3 weeks, and revenue gets recognized when the product is delivered. Most of what we book, I'd note, is recognized upon delivery, though there is one dynamic tied to our backlog: as the number of contracts grows and our payer mix widens, we're not just seeing contracted payers grant authorization — non-contracted payers are doing so as well. In fact, authorizations for MyoPro from non-contracted payers are ticking up somewhat, which shifts us toward recognizing revenue only once payment comes in. That pattern is beginning to show. It's encouraging in a way, since a wider set of payers is now covering the device.
All right, excellent. That's our final question. I may have overlooked this earlier during the call, but how much of the pipeline addition came via these newly established recurring referral channels, rather than, say, some of the direct sources used previously? And do you also have a percentage target for how you'd like that split to look going forward?
Referrals accounted for roughly 10% of pipeline additions and approximately 10% of orders in the fourth 1/4; regarding how we envision what success could resemble in the near term, our aim is for revenues from recurring sources to reach close to 1/2 of our revenues by the end of 2026. That, I believe, is the near term goal we're concentrating on.
All right. I appreciate your time in answering my questions. I'll return to the queue.
Hello there, good afternoon, everyone, and thank you for fielding our questions. To begin with regard to the German market, it's wonderful to observe how strongly it has expanded since the close of last year. I was simply curious whether you might offer some detail about which factors primarily drove that growth, and what your expectations are for how that market will perform in 2026.
My apologies, we lost part of what you said. To which market were you referring? The international one?
Germany, right.
So Germany's a sizable market, as you know — population north of 80 million, prevalence at 1%. That puts you at 800,000 people with the condition, plus all those incidence cases on top. Our folks have recruited quite a few O&P practices across that country successfully. The social court decisions we've received have been quite favorable. A large number of statutory health insurance carriers will cover MyoPro, so the reimbursement problems we deal with in the U.S. don't exist for us there in Germany. That's the reason it's such an attractive market — it expanded more than 40% — and we keep putting money into growing that business.
Great. Thanks for that. My second question is on the randomized controlled trial that's going on in University of Utah. If this study is successful, how will you use this data, in your commercial efforts, and where do you think it will help the most?
Good news — the IRB approval for this trial has just come through. It's a randomized controlled trial, comparing patients who have MyoPro against a control group of those without one; initial data should begin emerging before this year ends. Our intention is to leverage that, much as we've leveraged other studies, to persuade additional payers to cover MyoPro's expense, since it isn't experimental, isn't investigational, and qualifies as medically reasonable and necessary. That's our strategy — it will simply bolster the research already in print, which CMS and numerous other payers have accepted, exactly like the new Elevance agreement we signed and announced today.
Excellent. That's quite useful. Our final question concerns R&D work on MyoPro 3. Might you share a timeline for the 3.0 model? What key clinical and manufacturing benefits does the 3.0 offer compared with the 2X?
This represents a next generation platform. We're overhauling every aspect of MyoPro — from the chip inside the device, to the software out there, the sensing systems, the orthotic materials, the hand grasp capability, elbow motor, harness; it's a complete redesign of MyoPro aimed at delivering greater functional benefit for patients. It will be customizable, as the current one is, yet simply deliver more function, comfort, and ideally drive even stronger market adoption as a result.
Great. Thanks once more for fielding our questions. That covers everything from us.
Yes, I appreciate you answering my question, and congrats. What I wanted to ask about was this: as your company keeps expanding abroad, how does the gross margin percentage outside the country stack up against the one inside it, and where does the chance for operating leverage come in? Thanks.
On the subject of ASPs, I've frequently noted that when you look at the international side of things, it holds the second-highest ASP, behind only the Medicare allowable figure right here in the U.S. On the international side, gross margin ends up somewhat lower. With us sitting at roughly a 68% gross margin during the fourth 1/4, the international number is going to come in a bit beneath that.
What kind of room does the model give you to push that higher as revenue increases?
Well, I'd say that our production takes place entirely within the United States. When additional units flow through our American plant, the gross margin over in Germany is going to improve, in the same way that the gross margin for the whole company improves.
Great. Well, I appreciate you taking my questions, and best of luck to you all. Thanks a lot.
Thanks, Ed.
Okay, thank you, operator. So, what we've done across the past 6 to 9 months already shows movement toward our objectives of building a profitable company that keeps growing and tackling that sizable unmet need of chronic arm paralysis. For this year, we're anticipating a record quantity of MyoPro orders, with an increasing share coming from these recurring patient sources. With the fresh strategy for digital and TV advertising, plus the move into the new O&P and rehab hospital channels, we expect our customer acquisition costs to come down. Our reduced cost structure, along with these initiatives aimed at cutting our manufacturing costs, ought to produce gains in our gross margin. We keep innovating in product development so we can hold onto our market leadership position. Thanks to all of you for your questions and for your interest in Myomo. Have a nice evening.
This wraps up our call. We appreciate you joining the presentation today. At this point, you're free to leave the line.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Myomo, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Myomo, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.